Evidence map›Paper›PMID 32908978›Full record

ArticlebioRxiv : the preprint server for biology2020

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility.

Jessica A Plante, Yang Liu, Jianying Liu, Hongjie Xia, Bryan A Johnson, Kumari G Lokugamage, Xianwen Zhang, Antonio E Muruato, Jing Zou, Camila R Fontes-Garfias and 12 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Article
  3. Neurotropic Viruses, Astrocytes, and COVID-19.Frontiers in cellular neuroscience · 2021
    Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 1 country.

Jessica A PlanteWorld Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston TX, USA.
Yang LiuDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Jianying LiuInstitute for Human Infections and Immunity, University of Texas Medical Branch, Galveston TX, USA.
Hongjie XiaDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Bryan A JohnsonInstitute for Human Infections and Immunity, University of Texas Medical Branch, Galveston TX, USA.
Kumari G LokugamageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Xianwen ZhangDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Antonio E MuruatoInstitute for Human Infections and Immunity, University of Texas Medical Branch, Galveston TX, USA.
Jing ZouDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Camila R Fontes-GarfiasDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Divya MirchandaniWorld Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston TX, USA.
Dionna SchartonWorld Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston TX, USA.
John P BilelloGilead Sciences, Inc., Foster City, CA, USA.
Zhiqiang KuTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, USA.
Zhiqiang AnTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, USA.
Birte KalveramDepartment of Pathology, University of Texas Medical Branch, Galveston TX, USA.
Alexander N FreibergInstitute for Human Infections and Immunity, University of Texas Medical Branch, Galveston TX, USA.
Vineet D MenacheryInstitute for Human Infections and Immunity, University of Texas Medical Branch, Galveston TX, USA.
Xuping XieDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Kenneth S PlanteWorld Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston TX, USA.
Scott C WeaverWorld Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston TX, USA.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
The University of Texas Medical Branch at Galveston · USBrown Foundation · USGilead Sciences (United States) · US

Funding

UTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0M
Project 4 - Influenza - UABU19AI142759 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WHITLEY, RICHARD J. · 2019 to 2023
$37.5M
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
UTMB Clinical and Translational Science AwardTL1TR001440 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HOMMEL, JONATHAN DEAN · 2015 to 2024
$3.4M
Regulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health ThreatsR43AI145617 · NIAID · PLEX PHARMACEUTICALS, INC. · PI REMACLE, ALBERT, THOTA, SAMBAIAH · 2020 to 2021
$600k
NCATS NIH HHS TL1 TR001440NCATS NIH HHS UL1 TR001439NIAID NIH HHS R01 AI134907NIAID NIH HHS R01 AI153602NIAID NIH HHS R24 AI120942NIAID NIH HHS R43 AI145617NIAID NIH HHS U19 AI142759
6 · The paper itself

Abstract

A spike protein mutation D614G became dominant in SARS-CoV-2 during the COVID-19 pandemic. However, the mutational impact on viral spread and vaccine efficacy remains to be defined. Here we engineer the D614G mutation in the SARS-CoV-2 USA-WA1/2020 strain and characterize its effect on viral replication, pathogenesis, and antibody neutralization. The D614G mutation significantly enhances SARS-CoV-2 replication on human lung epithelial cells and primary human airway tissues, through an improved infectivity of virions with the spike receptor-binding domain in an "up" conformation for binding to ACE2 receptor. Hamsters infected with D614 or G614 variants developed similar levels of weight loss. However, the G614 virus produced higher infectious titers in the nasal washes and trachea, but not lungs, than the D614 virus. The hamster results confirm clinical evidence that the D614G mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increases transmission. For antibody neutralization, sera from D614 virus-infected hamsters consistently exhibit higher neutralization titers against G614 virus than those against D614 virus, indicating that (i) the mutation may not reduce the ability of vaccines in clinical trials to protect against COVID-19 and (ii) therapeutic antibodies should be tested against the circulating G614 virus before clinical development.

Identifiers

PMID32908978
PMCPMC7480025
OpenAlexW3082360167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.